<!-- page 1 -->

05/08/2008 

Dear Eloise 

The Royal College of Pathologists have no comments to submit at this stage of the consultation. 

Best wishes 

xxxxxxxxxxxxx 

## **NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE** 

## **Single technology appraisal (STA)** 

## **Infliximab for the treatment of acute exacerbations of ulcerative colitis** 

## **Appraisal consultation document** 

Dear Consultees and Commentators, 

You are invited to comment on the attached appraisal consultation document (ACD) for the above appraisal. A CD of the ACD and evaluation report will be sent to you. 

The Appraisal Committee is interested in receiving your comments on the ACD under the following general headings. 

- i) Do you consider that all of the relevant evidence has been taken into account? 

- ii) Do you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence, and that the preliminary views on the resource impact and implications for the NHS are appropriate? 

- iii) Do you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS? 

- iv) Are there any equality related issues that need special consideration that are not covered in the ACD? 

If you wish to comment on the evaluation report, please do so under a separate heading from your comments on the ACD. 



<!-- page 2 -->

We prefer to receive comments in electronic format, either by email to Eloise Saile Eloise.Saile@nice.org.uk or on compact or floppy disk. Please use Microsoft Office software products. Comments sent by post should be addressed to Eloise Saile, Technology Appraisal Project Manager, at the above address. 

Please note that your comments, along with a summary table of these comments and the action taken in response to them, will be released to consultees and commentators with the final appraisal determination (FAD) for this appraisal, and published on the Institute’s website. 

In line with the Guide to Technology Appraisals Process (April 2004; sections 4.5.2.7 and 4.5.2.10), we do not expect you to submit any information which is commercial in confidence or academic in confidence with your comments on the ACD and evaluation report. 

In the light of comments received, the Appraisal Committee will reconsider the ACD at a meeting on 18th September,2008. In order for your views to be included in the papers for this meeting, your comments must be submitted before 5pm on 3[rd] September, 2008. 

The ACD and evaluation report will be posted on the Institute’s website on 12[th] August, 2008 (5 working days from receipt of letter). People who are not formal consultees or commentators for this appraisal can comment on the ACD through an email link on the website. However, we do **not** wish to receive comments from formal consultees and commentators via the website. **Please send your comments directly to the Technology Appraisal Project Manager, either by email or by post.** 

I must emphasise that the documents enclosed with this letter, and their contents, are confidential until they are published on the Institute’s website. They are released to you only for the purpose of informing the Appraisal Committee’s consideration of this technology. Accordingly, the documents and their contents should only be divulged to those individuals within your organisation who need to see them to enable you to prepare your response. You must ensure that anyone who sees these documents is aware of their confidentiality. 

The use of any information contained in the ACD to make investment decisions regarding any shares or other securities, or the passing of such information to someone else for such use, may constitute insider dealing, which is a criminal offence under section 52 of the Criminal Justice Act 1993. It may also be an offence to encourage someone else to deal in shares or securities, the price of which would be affected by the disclosure to the public of any information contained in the ACD. 

Yours sincerely, 



<!-- page 3 -->

Dr Carole Longson Director, Centre for Health Technology Evaluation 

attached: 

Appraisal consultation document (ACD) Evaluation report 

The information contained in this message and any attachments is intended for the addressee(s) only. If you are not the addressee, you may not disclose, reproduce or distribute this message. If you have received this message in error, please advise the sender and delete it from your system. Any personal data sent in reply to this message will be used in accordance with provisions of the Data Protection Act 1998 and only for the purposes of the Institute's work. 

All messages sent by NICE are checked for viruses, but we recommend that you carry out your own checks on any attachment to this message. We cannot accept liability for any loss or damage caused by software viruses. 

http://www.nice.org.uk 

_____________________________________________________________________ 

___ This e-mail has been scanned for all viruses by Star. The service is powered by MessageLabs. For more information on a proactive anti-virus service working around the clock, around the globe, visit: http://www.star.net.uk 

_____________________________________________________________________ 

___ <UC Evaluation Report.pdf><Ulcerative Colitis - infliximab ACD.pdf> 

Dr.D.S.Kumararatne Consultant Immunologist, Department of Clinical Immunology, Box 109, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. Tel 441223217166, Fax 441223217794 email dsk22@cam.ac.uk 

Tel for secretary ;  441223586830 

_____________________________________________________________________ 

___ This e-mail has been scanned for all viruses by Star. The service is powered by MessageLabs. For more information on a proactive anti-virus service working around the clock, around the globe, visit: http://www.star.net.uk 



<!-- page 4 -->

_____________________________________________________________________ 

___ 

__________________________ 

Delivered via MessageLabs 

__________________________ 

